Moderna Inc. said it will reduce annual spending by about $1.5 billion by 2027 as the company continues to cut costs to ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Moderna (NASDAQ:MRNA) accelerates cost cuts, trimming 2026 GAAP operating expenses by up to $500 million as COVID-19 vaccine ...

From STAT’s Jason Mast: Moderna said this morning in its earnings report it planned to cut costs by around $1.5 billion by ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Moderna on Thursday pushed back the time frame for likely approval of a combination vaccine meant to protect against both ...

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...